25th Annual Offering of Critical Issues in Tumor Microenvironment, Angiogenesis and Metastasis: From Bench to Bedside to Biomarkers
Approval of multiple molecularly targeted agents for therapy of cancer and other diseases (e.g., age-related macula degeneration) has heralded a new era. For tumor biology, the major challenges in the field are now how to optimally use these novel drugs as monotherapies or in combination with other therapies to extend the survival advantage obtained so far, and how to prevent tumor recurrence. These may be best achieved by bringing back and forth between bench and bedside the lessons and the new concepts that emerged from the recent clinical and preclinical experience with molecularly targeted agents.
The objective of this course is to discuss our current understanding of tumor microenvironment, the formation and function of new vessels in tumors, and their relationship with metastasis and outcome of various treatments. The focus will be placed on their pathophysiological significance and clinical relevance, with particular emphasis on clinical translation and biomarkers.
Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Harvard Medical School designates this educational activity for a maximum of 23 AMA PRA Category 1 Credit(s)™.
Rakesh K. Jain, Ph.D., Andrew Werk Cook Professor of Tumor Biology, Harvard Medical School; Director, E.L. Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA